What Royalty Pharma does

Royalty Pharma (NASDAQ: RPRX) is the world's largest buyer of biopharmaceutical royalties and a leading funder of late-stage clinical development. Founded in 1996 by Pablo Legorreta, the firm acquires royalty interests in marketed and development-stage therapies from biopharmaceutical companies, academic institutions, and inventors, providing non-dilutive capital in exchange for a share of future product revenues or development milestones. Over its history, Royalty Pharma has deployed more than $25 billion across more than 80 royalty acquisitions and holds over 60% of the global market share in its category.

The company's portfolio spans more than 40 marketed and development-stage products across cystic fibrosis, oncology, autoimmune disease, neuroscience, and rare disease. Key revenue-generating assets include Trikafta/Alyftrek (Vertex), Trelegy (GSK), Evrysdi (Roche), Tremfya (Johnson & Johnson), Tysabri (Biogen), and Voranigo (Servier). Royalty Pharma's business model rests on three mechanics: (i) acquisitions of existing royalty streams from rights-holders seeking liquidity, (ii) structured funding of late-stage clinical development in exchange for future royalties (e.g., the $2 billion Revolution Medicines arrangement and the $500 million Johnson & Johnson JNJ-4804 co-funding), and (iii) hybrid structures combining milestone payments with royalty rights. Revenue is generated as a percentage of underlying product net sales, with portfolio receipts totaling $3,254 million in FY2025 and $925 million in Q1 2026 (10% YoY growth).

In May 2025, Royalty Pharma internalized its external manager, RP Management LLC, simplifying its corporate structure. The firm is expanding its geographic footprint with a new Hong Kong office and Asia-Pacific leadership, has appointed a Head of AI to institutionalize data-driven sourcing and diligence, and continues to target 10%+ long-term annual top-line growth.

Name

Royalty Pharma

Legal name

Royalty Pharma plc

Website

https://royaltypharma.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Royalty Pharma (NASDAQ: RPRX) is the world's largest buyer of biopharmaceutical royalties, acquiring cash-flow interests in marketed and late-stage therapies from biopharma companies and academic institutions. Founded in 1996, it has deployed over $25 billion across 80+ transactions and holds 60%+ global market share.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Royalty Financing

NAICS

Music Publishers (51223)

SIC

Patent Owners & Lessors (6794)

akta.pro primary industry

Private Credit — Royalty & IP-Backed Finance (FSAHAJAM)

Keywords

• Biopharmaceutical royalty financing
• Royalty acquisition services
• Synthetic royalty funding
• R&D co-funding solutions
• Pharmaceutical royalty investments

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Royalty Receipts: Royalty Pharma collects royalties based on a percentage of net sales of commercial products from its portfolio of over 35 commercial products including Trikafta, Trelegy, Evrysdi, Tremfya, Tysabri, Xtandi, Voranigo, Imbruvica, Cabometyx, Promacta, Trodelvy, Spinraza, Amvuttra, and others. Royalty Receipts grew 13% to $887 million in Q1 2026.
2. Milestones and Other Contractual Receipts: Royalty Pharma receives sales-based or regulatory milestone payments from development-stage investments when products achieve regulatory approvals or sales milestones. In Q1 2026, Milestones and other contractual receipts were $38 million.
3. Synthetic Royalty Funding: Royalty Pharma provides upfront capital to biotech companies in exchange for future royalty payments based on product sales. This includes transactions with companies like Denali Therapeutics ($275M), Zymeworks ($250M), and co-funding arrangements where Royalty Pharma receives milestone and royalty payments.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Royalty Pharma buys and structures royalty interests in biopharmaceutical products, providing non-dilutive capital to drug developers. The company acquires existing royalty streams from universities, hospitals, foundations, and biotech companies, and also creates new synthetic royalty arrangements that deliver upfront cash in exchange for future royalty payments based on product sales. Royalty Pharma has deployed more than $25 billion across over 80 royalty acquisitions since 1996, assembling a portfolio of over 35 commercial products and approximately 19 development-stage candidates.

Product overview

Royalty Pharma operates as the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences, offering a platform of funding solutions including royalty acquisitions, synthetic royalties, launch and development capital, and M&A facilitation. The company has assembled a portfolio of royalties entitling it to payments based on top-line sales of leading therapies. Royalty Pharma's portfolio includes royalties on over 35 commercial products spanning multiple therapeutic areas: cystic fibrosis franchise (Trikafta, Alyftrek), respiratory (Trelegy), rare disease (Evrysdi, Spinraza), immunology (Tremfya), neuroscience (Tysabri), and oncology (Xtandi, Imbruvica, Voranigo, Trodelvy, Imdelltra). Additionally, the portfolio includes approximately 19 development-stage product candidates such as daraxonrasib, Myqorzo, Ziihera, neladalkib, litifilimab, Avlayah, and obexelimab. The company also sponsors the Accelerating Bio-Innovation Conference in partnership with MIT and University of Cambridge, and recently launched the Royalty Pharma Translational Prize, a $1 million annual award recognizing achievements in translational medicine.

Differentiator

Problem solved

Functional benefit

Brands

• Royalty Pharma Translational Prize: A $1 million annual award recognizing exceptional achievements in translational medicine, administered by an independent committee chaired by Nobel Laureate Sir Gregory Winter
• Accelerating Bio-Innovation Conference

Products and services

• Royalty Acquisition (Existing Royalties)
• Synthetic Royalty Funding
• Launch & Development Capital
• M&A Facilitation

Quantifiable outcome

• 13% year-over-year Royalty Receipts growth to $887M in Q1 2026
• +4 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• Johnson & JohnsoncoreStrategic or Co-development Partner · 30 March 2026Royalty Pharma entered into a $500 million R&D co-funding agreement with Johnson & Johnson to develop JNJ-4804, an investigational autoimmune drug. The collaboration focuses on IL-23 and TNF pathways for chronic immune-mediated diseases. Royalty Pharma provides clinical trial funding in exchange for future royalties on sales.
• Vera TherapeuticsminorStrategic or Co-development Partner · 5 March 2026Christopher Hite, Executive Vice President and Vice Chairman at Royalty Pharma, was appointed to Vera Therapeutics' Board of Directors to support the company approaching potential launch of atacicept for IgA nephropathy.
• Teva PharmaceuticalscoreStrategic or Co-development Partner · 11 January 2026Royalty Pharma and Teva entered into a funding agreement of up to $500 million to accelerate development of Teva's anti-IL-15 antibody TEV-'408 for treating vitiligo. The agreement includes $75 million for Phase 2b study funding with option to provide additional $425 million for Phase 3 development.
• BiogencoreStrategic or Co-development Partner · 12 February 2025Royalty Pharma provides R&D funding of up to $250 million for Biogen's litifilimab, a first-in-class investigational drug in Phase 3 for lupus (SLE and CLE). Royalty Pharma receives regulatory milestones and mid-single digit royalties on worldwide sales.
• MIT (Massachusetts Institute of Technology)minorStrategic or Co-development Partner · 4 March 2024Royalty Pharma made a $3 million gift to support the MIT-Royalty Pharma Faculty Founder Initiative, a two-year program helping biotech innovators and faculty entrepreneurs commercialize research. Since 2021, the initiative has supported 21 faculty entrepreneurs and spawned 16 startups.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• HealthCare Royalty Partners (HCR): One of the largest dedicated healthcare royalty acquisition and financing firms globally. Directly comparable to Royalty Pharma in business model (acquiring biopharma royalties, providing synthetic royalties, R&D co-funding) and target customers (biotech and pharma).
• Blackstone Life Sciences: Blackstone's life sciences arm invests in biopharma royalties, R&D financing, and development-stage therapeutics. Directly competes for biopharma royalty deals (Royalty Pharma itself bought the Amvuttra royalty from Blackstone in 2025), making it a key capital peer.
• Innovatus Capital Partners: Active acquirer of biopharma royalties and structured healthcare debt. Operates a similar direct-royalty and structured-financing model targeting biotech and pharma, making it a focused direct peer in the dedicated royalty finance space.
• XOMA Corporation: Public biotech royalty aggregator that acquires milestone and royalty rights on clinical-stage and commercial biopharma assets. Smaller and more royalty-pure-play than Royalty Pharma but operates the same underlying economic model.
• Ligand Pharmaceuticals: Operates a royalty-driven business model acquiring rights to biopharma assets and earning royalties on partnered products. Smaller scale than Royalty Pharma but structurally similar in monetizing biopharma IP through royalty economics.
• Sagard Healthcare Royalty Fund: Dedicated biopharma royalty acquisition fund. Operates the same direct-royalty acquisition model targeting biotech and pharma counterparties, making it a focused direct peer though smaller in scale than Royalty Pharma.

Broad incumbents

• OMERS Life Sciences: The pension fund's life sciences investment arm has been an active acquirer of biopharma royalties and structured financing deals. Operates with broader investment mandates beyond royalties, making it a broader incumbent rather than a pure-play peer.
• KKR Health Care Strategic Growth: KKR's healthcare-focused investment platform participates in biopharma royalty, structured debt, and growth equity deals. Larger and more diversified than Royalty Pharma across healthcare subsectors, but overlaps in biopharma royalty financing.
• OrbiMed Advisors: Large healthcare-dedicated investment firm with royalty/structured-finance activities alongside private equity, venture, and public equity strategies. Overlaps with Royalty Pharma in biopharma royalty and structured financing deals but operates across a much broader healthcare mandate.

Emerging players

• BridgeBio Pharma: Genetic-disease focused biotech that uses non-dilutive financing structures (royalty-like deals and asset-level financing). Less of a pure royalty buyer but increasingly engages in similar structured funding arrangements for late-stage clinical assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Royalty Pharma